Olmetab
Generic Name
Olmesartan Medoxomil
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetab 10 mg tablet | ৳ 3.50 | ৳ 35.00 |
Description
Overview of the medicine
Olmetab 10 mg Tablet contains Olmesartan Medoxomil, an Angiotensin II Receptor Blocker (ARB) used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily.
Uses & Indications
Dosage
Adults
The usual recommended starting dose is 10 mg once daily. The dose can be increased to 20 mg once daily after two weeks if blood pressure is not adequately controlled. The maximum recommended dose is 40 mg once daily.
Elderly
No initial dose adjustment is generally required for elderly patients, but the maximum dose should be carefully monitored.
Renal_impairment
For patients with moderate to severe renal impairment (creatinine clearance <40 mL/min), a lower starting dose (e.g., 5 mg) may be considered, and careful monitoring is recommended.
How to Take
Olmetab tablets should be swallowed whole with sufficient liquid, with or without food, at approximately the same time each day.
Mechanism of Action
Olmesartan is a prodrug that is hydrolyzed to olmesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. This leads to vasodilation, reduction in peripheral vascular resistance, and decreased blood pressure.
Pharmacokinetics
Onset
Blood pressure reduction begins within 1-2 weeks; full effect typically within 4 weeks.
Excretion
Approximately 35-50% is excreted in urine and 50-65% in feces via bile.
Half life
Approximately 13 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract. Bioavailability is approximately 26%. Peak plasma concentration is reached within 1-2 hours.
Metabolism
Olmesartan medoxomil is a prodrug and is rapidly and completely hydrolyzed to olmesartan during absorption from the gastrointestinal tract. No further metabolism of olmesartan occurs.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Second and third trimesters of pregnancy.
- Biliary obstruction.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity. Concurrent use is not recommended.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration, including possible acute renal failure, particularly in patients with pre-existing renal impairment.
Diuretics (e.g., Furosemide, Hydrochlorothiazide)
Increased risk of hypotension, especially at the start of treatment.
Potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes
Increased risk of hyperkalemia.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension and possibly tachycardia; bradycardia could occur. Treatment is symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Administer IV fluids to support blood pressure.
Pregnancy & Lactation
Olmetab is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. It is not recommended during the first trimester. Due to the potential for adverse effects on the nursing infant, it is not recommended during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Second and third trimesters of pregnancy.
- Biliary obstruction.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity. Concurrent use is not recommended.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration, including possible acute renal failure, particularly in patients with pre-existing renal impairment.
Diuretics (e.g., Furosemide, Hydrochlorothiazide)
Increased risk of hypotension, especially at the start of treatment.
Potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes
Increased risk of hyperkalemia.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension and possibly tachycardia; bradycardia could occur. Treatment is symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Administer IV fluids to support blood pressure.
Pregnancy & Lactation
Olmetab is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. It is not recommended during the first trimester. Due to the potential for adverse effects on the nursing infant, it is not recommended during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from the date of manufacture
Availability
Available in pharmacies and hospitals
Approval Status
Approved
Patent Status
Off-patent
Clinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of Olmesartan Medoxomil in reducing blood pressure in patients with essential hypertension. Trials have shown sustained blood pressure control and a favorable tolerability profile.
Lab Monitoring
- Monitor blood pressure regularly.
- Assess renal function (serum creatinine, blood urea nitrogen) periodically, especially in patients with pre-existing renal impairment or those on high doses.
- Monitor serum potassium levels, especially in patients with renal impairment or those taking potassium-sparing diuretics or potassium supplements.
Doctor Notes
- Always assess patient's renal function and serum potassium levels before initiating therapy and periodically thereafter.
- Counsel patients on the importance of adherence to medication and lifestyle modifications.
- Avoid use in pregnant women, especially in the second and third trimesters.
- Be cautious when co-administering with NSAIDs due to potential renal adverse effects.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not stop taking Olmetab without consulting your doctor, even if you feel well.
- Inform your doctor about all other medications you are taking, including over-the-counter drugs and herbal supplements.
- Report any unusual side effects or symptoms to your doctor immediately.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olmetab may cause dizziness or fatigue. Patients should be cautious when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Maintain a healthy diet low in sodium and saturated fats.
- Engage in regular physical activity as advised by your doctor.
- Limit alcohol consumption and avoid smoking.
- Manage stress effectively through relaxation techniques.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olmetab Brand
Other medicines available under the same brand name
